

Haematologica
HAEMATOL/2016/143644
Version 3

Ruxolitinib versus best available therapy in patients with Polycythemia
Vera: 80 Week follow up from the RESPONSE trial

Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, and Jean-Jacques Kiladjian

Disclosures: SV received funding from and participated in advisory boards for Incyte Corporation. AMV served as a consultant for Novartis, participated in speakers bureaus for Novartis and Shire, and received research funding from Novartis. MG received travel reimbursements from Amgen, Roche, Novartis, and Shire. TM served as a consultant for Novartis and Janssen-Cilag. SD received honoraria and research funding from Novartis. CNH received honoraria from Sanofi, Novartis, and Baxter; served on speakers bureaus for Sanofi, Novartis, Shire, and Baxter; received research funding from Novartis; and received travel reimbursement from Novartis. KK received honoraria from Novartis. CB received honoraria from Novartis and Shire. FPan received honoraria from Novartis, Bristol-Myers Squibb, and Roche; served as a consultant for Bristol Myers Squibb and Ariad; received research funding from Novartis; and received travel reimbursements from Novartis and Roche. BM served on speakers bureaus for Novartis and Bristol-Myers Squibb. CBM received honoraria and served on a speakers bureau and as a consultant for Incyte Corporation. RM received honoraria and served as a consultant for Novartis and received research funding from Incyte Corporation, Gilead, CTI BioPharma, and Celgene. MMJ and HZ are employees and stockholders of Incyte Corporation. JL, NF, and DH are employees and stockholders of Novartis. J-JK served as a consultant for Novartis, Shire, and Incyte Corporation and received research funding from Novartis and AOP Orphan Pharmaceuticals. FPas, PZ, MH, MC, VR, and IB had no conflicts of interest to disclose.

Contributions: SV, AMV, MG, TM, SD, FPas, CNH, FPan, PZ, KK, CB, MH, BM, CBM, MC, VR, IB, RM, and J-JK contributed to the collection and analysis of data and to the development of the manuscript draft. MMJ contributed to the study design, analysis of data, and to the development of the manuscript draft. HZ and NF contributed to the analysis of data and to the development of the manuscript draft. JL and DH contributed to the execution of the study, to the analysis and interpretation of data, and to the development of the manuscript draft.